Quiet end for flashy upstart, the PD-(L)1 reckoning that wasn't, Big Pharma's Covid-19 year, and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
I was somewhat detached from daily news this week to work on a special feature, which gave me a special perspective on the excellent reporting from my colleagues. The team is growing and it shows. Big thanks to all of our readers for making it possible.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.